Treatment of Morbid Obesity with Intragastric Balloon in Association with Diet

Doldi, S B; Micheletto, G; Perrini, M N; Librenti, M. C.; Rella, S

doi:10.1381/096089202762252398

Cited by 94 publications

(61 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously published results revealed an average weight loss of 12-15 kg over 6 months with an excellent safety profile [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] . The Spatz Adjustable balloon was introduced in 2010 as the first IGB approved for 1 year implantation while featuring an adjustability function that afforded balloon volume changes as needed.…”

Section: Introductionmentioning

confidence: 99%

One year adjustable intragastric balloon: safety and efficacy of the Spatz3 adjustable balloons

Machytka

Brooks²,

Bužga

et al. 2014

F1000Res

View full text Add to dashboard Cite

Discuss this article AbstractThe Spatz3 Adjustable balloon system is approved for 1 year Background: implantation and allows multiple changes in the balloon volume during the course of implantation. Other intragastric balloons are currently approved for 6 months and their balloon volumes cannot be adjusted after implantation.To determine the efficacy and safety of the Spatz3 adjustable balloon Aim: system.Seventy seven consecutive patients (66 females and 11 males) in Methods: two medical centers were implanted with the Spatz3 adjustable balloon device and were followed prospectively. The patients' mean BMI was 37.2; the mean weight was 108.7 kg; the mean age was 41 (16-68); the mean balloon volume was 469 ml (450-500 ml). Adjustments were made for intolerance or weight loss plateau.The mean weight loss at 1 year was 17.2 kg with 15.9 % weight loss Results: and 42.9 % Excess Weight Loss (%EWL). Eighteen patients underwent balloon volume adjustments: three downward adjustments of 100 -150 cc which alleviated early intolerance; 15 upward adjustments (mean 320 ml; range 200-500) at a mean 4.1 months (range 2-5 months) yielded additional mean wt loss of 8.2 kg (range 0-25 kg) after the adjustment. Three balloons were removed before the 1 year completion date due to intolerance and three others were removed for other reasons (pregnancy, gall bladder surgery, and alcoholism). There was one episode of gastric ulceration which required endoscopic therapy and balloon removal. There were no deflations or perforations.The Spatz3 adjustable balloon is a safe and effective treatment Conclusions: for weight loss. The adjustability function can yield greater weight loss for those who show weight loss plateau and can mitigate intolerance.

show abstract

Section: Introductionmentioning

confidence: 99%

One year adjustable intragastric balloon: safety and efficacy of the Spatz3 adjustable balloons

Machytka

Brooks²,

Bužga

et al. 2014

F1000Res

View full text Add to dashboard Cite

show abstract

“…Balloon tolerability was very good in our series; we did not have to remove any balloon before the determined time and this is better than that published in the literature, which describes 4.2-11% of patients who required balloon removal due to lack of tolerability or complications (24,(27)(28)(29)32).…”

Section: Discussionmentioning

confidence: 49%

“…Other authors have found that pre-surgical weight loss is a predictive factor for a higher loss weight during post-surgical evolution (6,17), and would help to select those obese population who would benefit most from bariatric surgery. The IGB in morbid obesity is a temporal treatment given as a second step when the multidisciplinary nutritional treatment fails (23), because it results in greater weight loss compared to conventional diet treatments (24)(25)(26)(27), although it is not clear whether it is more effective (28,29).…”

Section: Obesity (Bmi ≥ 30 Kg/mmentioning

confidence: 99%

“…One of the potential future indications for the intragastric balloon could be its use as a bridge-treatment until bariatric surgery (27), not only in order to achieve weight loss before surgery, decrease comorbidity, ease the surgical technique, and decrease postsurgical morbidity, but also to improve comorbidities, facilitate the surgical technique, potentially reduce any surgical complications, or for use in special populations such as super-obese patients (7). More frequently now in clinical practices and in many surgical units, weight loss is attempted before bariatric surgery using intragastric balloons (IGB) in conjunction with strict diets (27,30).…”

Section: Obesity (Bmi ≥ 30 Kg/mmentioning

confidence: 99%

“…More frequently now in clinical practices and in many surgical units, weight loss is attempted before bariatric surgery using intragastric balloons (IGB) in conjunction with strict diets (27,30). However, this therapeutic approach currently presents a dubious utility.…”

Section: Obesity (Bmi ≥ 30 Kg/mmentioning

confidence: 99%

See 2 more Smart Citations

Usefulness of an intra-gastric balloon before bariatric surgery

et al. 2017

View full text Add to dashboard Cite

Introduction: There are only few reports regarding the use of intragastric-balloons (IGB ® ) to achieve weight loss and subsequently decrease surgical complications. In this study, we try to assess whether presurgery weight loss using IGB decreases the postsurgical mortality after bariatric surgery.Material and methods: This is a prospective case-control study. We matched 1:1 by gender, age (± 10 y-o) and type of surgery (sleeve resection [LSG] or gastric bypass [LGBP]), matching cases (A) and controls (H, from a historic cohort). Morbidly obese patients with an indication for bariatric surgery were included in the study. Cases (A) were recruited from an ongoing clinical trial, and the controls (H) came from a historic cohort prior to the start of the clinic trial. The presurgical weight loss in group A was reached by IGB combined with diet, versus only diet in group H.Results: We included 58 patients, 65.5% women, 69% LGBP/31% LSG. The mean age of group A was 42 and 43.4 years old for group H. ASA III of 24.1% group A vs 58.6% group H, p = 0.012. The mean total weight loss (TWL) before surgery was greater in group A (16.2 kg, SD 9.75) than in group H (1.2 kg, SD 6.4), p < 0.0001. The % of EWL before surgery was 23.5 (SD 11.6) in group A vs 2.4 (SD 8) in group H, p < 0.001. Hospital stay was seven days for group A, and eight days for group H, p = 0.285. The rate of unsuccessful IGB treatment to accomplish the scheduled weight loss was 34.5%. The balloon morbidity was 17.2% (6.9% severe). All in all, morbidity (due to bariatric surgery and IGB) was 41% in both groups. Postsurgical morbidity moderate-severe was 20.3% in group A (6.9% severe) and 27.3% in group H (17.2% severe) without statistical significance. One patient died in group H (mortality rate, 3.44%).Conclusion: Preoperative IGB treatment in morbid obesity has not been found to be effective at decreasing postsurgical morbidity LSG and LGBP, despite the fact that it acheives a greater weight loss than diet and exercise.

show abstract